New pill shows promise in early trial for tough cancers
NCT ID NCT06566079
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Participants take one capsule daily, and researchers will monitor side effects and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ISM6331 (a drug taken orally as a capsule once daily)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced mesothelioma or other solid tumors who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 100 participants, so the drug may not prove safe or effective. Side effects are unknown, and it may not work for all tumor types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
-
NEXT Oncology - Austin
RECRUITINGAustin, Texas, 78758, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at HealthONE
RECRUITINGDenver, Colorado, 80218, United States
-
Shanghai Pulmonary Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, China
-
The University of Chicago Medical Center - Duchossois Center for Advanced Medicine
RECRUITINGChicago, Illinois, 60637, United States
-
University Hospitals Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
-
University of Pennsylvania - Abramson Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States